Printer Friendly

Nasal vaccine against Helicobacter pylori under development.

Nasal vaccine against Helicobacter pylori under development. Eurocine Vaccines has signed an agreement with research company HeliCure to develop a nasal vaccine against H pylori, a bacterium that causes gastric ulcers and gastric cancer. The project is in the pre-clinical development phase and is planned for tests in humans within two to three years. In addition to gastric ulcers, every year approximately 1 million people develop gastric cancer. The strong connection with H pylori means that a vaccine, which prevents infection with the bacterium, will also reduce the risk of gastric cancer.

COPYRIGHT 2009 Nelson Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:New vaccines
Publication:Medical Laboratory Observer
Article Type:Brief article
Geographic Code:1USA
Date:Dec 1, 2009
Previous Article:CD4 level predicts cancer risk in HIV patients.
Next Article:In memoriam.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters